BRCA1 and cancer: Failure to resolve DSBs owing to loss-of-function mutations in genes encoding key players in the DNA damage response (DDR) — such as BRCA1, BRCA2 — and HR deficiency (HRD) has paved the way toward DDR-directed therapeutic strategies in several cancers (6).